Description
Key facts
CAS number:936563-96-1,
Purity:>99%,
Form:SolidSee storage information,
Molecular weight:440.5 Da,
Molecular formula:C25H24N6O2,
PubChem:24821094,
Nature:Synthetic,
Solubility:Soluble in DMSO to 50mM,
Biochemical name:Ibrutinib,
Biological description:Highly potent, irreversible Bruton tyrosine kinase (BTK) inhibitor (IC50 = 0.5nM). Inhibits autophosphorylation of BTK IC50 = 11 nM), and phophorylation of PLCγ (IC50 = 29 nM) and ERK (IC50 = 13 nM). Potently inhbits BLK, BMS, FGR, EGFR and ITK kinases. Blocks B-cell antigen receptor (BCR) activation. Cytotoxic to chronic lymphocytic leukemia (CLL) cells.,
Canonical smiles:C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N,
Isomeric smiles:C=CC(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N,
InChi:InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1,
InChiKey:XYFPWWZEPKGCCK-GOSISDBHSA-N,
IUPAC Name:1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
Product details:
Solutions in DMSO may be stored at -20°C for up to 3 months.
Properties and Storage Information:
Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C, Storage information-Store under desiccating conditions
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
Lyn BLK Ret EGFR TDP1 FGFR2 Smad3 Yes1 BTK and Flt3/CD135 represent a diverse group of proteins involved in various signaling pathways. Lyn a Src family tyrosine kinase is expressed in hematopoietic cells and plays roles in signal transduction. BLK and Yes1 are also tyrosine kinases belonging to the Src family with expression largely in B cells and epithelial cells respectively. Ret a receptor tyrosine kinase is significant in nervous system development. EGFR a receptor tyrosine kinase known as ErbB1 or HER1 is widely expressed in epithelial tissues and weighs approximately 134 kDa. TDP1 a DNA repair enzyme is expressed in cell nuclei. FGFR2 a receptor tyrosine kinase is present in mesenchymal and epithelial tissues. Smad3 a signaling mediator functions downstream in transforming growth factor-beta signaling. BTK a non-receptor tyrosine kinase functions in B cell development while Flt3/CD135 another receptor tyrosine kinase is expressed in hematopoietic progenitor cells. BMX a tyrosine kinase shows expression in various tissues including endothelial and epithelial cells.
Biological function summary
These proteins perform diverse and significant roles. Lyn BLK Yes1 and BTK participate in immune cell signaling pathways modulating cell activation and differentiation. Ret functions in cell growth and neuronal development often forming complexes with co-receptors like GFRα. EGFR is important for cell growth differentiation and survival often partnering with ligands like EGF. TDP1 acts in DNA repair mechanisms while FGFR2 influences cell proliferation and differentiation. Smad3 mediates TGF-beta-induced transcriptional responses and Flt3/CD135 regulates hematopoietic progenitor cell survival and proliferation. BMX contributes to cellular processes like growth and survival through signaling modulation.
Pathways
These proteins integrate into critical signaling networks. Lyn and BTK engage in the B cell receptor pathway interfacing with proteins such as Syk and PLCγ2. EGFR plays a role in the MAPK/ERK pathway interacting with GRB2 and SOS to relay signals. FGFR2 also participates in the MAPK/ERK pathway influencing cell division and differentiation. Ret links to the PI3K/AKT pathway interacting with Shc and phosphoinositide 3-kinase modulating cell growth and survival. Smad3 as part of the TGF-beta pathway collaborates with Smad4 to control gene expression.
These proteins associate with various conditions. Lyn and BTK have links to chronic lymphocytic leukemia (CLL) where aberrant signaling leads to uncontrolled B cell proliferation. EGFR mutations are common in non-small cell lung cancer influencing tumor growth and resistance to therapy. Ret mutations associate with multiple endocrine neoplasia type 2 (MEN2) driving abnormal cancerous growths in endocrine tissues. FGFR2 mutations relate to skeletal disorders like Apert syndrome while Smad3 mutations connect to vascular diseases like aneurysms. Flt3 mutations are commonly found in acute myeloid leukemia (AML) influencing uncontrolled cell proliferation. BMX involvement appears in prostate cancer affecting tumor progression and resistance. These connections highlight the importance of targeted therapies such as BTK inhibitors like ibrutinib which inhibit BTK's role in disease pathways.
